SWOT Analysis for Vivos Therapeutics Inc

Add SWOT widget to your site/app

Rising Net Cash Flow and Cash from Operating activity
Stocks whose current price is 20% higher than week low, and more than previous close
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Annual Net Profits improving for last 2 years
Top Gainers
Stock with Low PE (PE < = 10)
Volume Shockers
High Volume, High Gain

Rising Net Cash Flow and Cash from Operating activity

Stocks whose current price is 20% higher than week low, and more than previous close

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Company able to generate Net Cash - Improving Net Cash Flow for last 2 years

Annual Net Profits improving for last 2 years

Top Gainers

Stock with Low PE (PE < = 10)

Volume Shockers

High Volume, High Gain

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Oversold by Money Flow Index (MFI)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Highest fall from 52 Week High
Near 52 Week Low
Low Piotroski Score : Companies with weak financials
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
Declining profits every quarter for the past 2 quarters
Declining Revenue every quarter for the past 2 quarters
Stocks Underperforming their Industry Price Change in the Quarter

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Oversold by Money Flow Index (MFI)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Highest fall from 52 Week High

Near 52 Week Low

Low Piotroski Score : Companies with weak financials

Weak performer : Stock lost more than 20% in 1 month

Weak Momentum: Price below Short, Medium and Long Term Averages

Declining profits every quarter for the past 2 quarters

Declining Revenue every quarter for the past 2 quarters

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month
Mutual Funds Increased Shareholding over the Past Two Months
MFs increased their shareholding last quarter
Mf buying for 2 months

Mutual Funds Increased Shareholding in Past Month

Mutual Funds Increased Shareholding over the Past Two Months

MFs increased their shareholding last quarter

Mf buying for 2 months

Red Flags: Weakening Technicals and Share Price Decline

Red Flags: Weakening Technicals and Share Price Decline

Vivos Therapeutics Inc SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Vivos Therapeutics Inc has 10 Strengths, 11 Weaknesses, 4 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Rising Net Cash Flow and Cash from Operating activity

Stocks whose current price is 20% higher than week low, and more than previous close

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Company able to generate Net Cash - Improving Net Cash Flow for last 2 years

Annual Net Profits improving for last 2 years

Top Gainers

Stock with Low PE (PE < = 10)

Volume Shockers

High Volume, High Gain

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Oversold by Money Flow Index (MFI)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Highest fall from 52 Week High

Near 52 Week Low

Low Piotroski Score : Companies with weak financials

Weak performer : Stock lost more than 20% in 1 month

Weak Momentum: Price below Short, Medium and Long Term Averages

Declining profits every quarter for the past 2 quarters

Declining Revenue every quarter for the past 2 quarters

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month

Mutual Funds Increased Shareholding over the Past Two Months

MFs increased their shareholding last quarter

Mf buying for 2 months

Red Flags: Weakening Technicals and Share Price Decline